港股異動 | 鷹瞳科技漲超15%，多家投行首予買入評級
uSMART盈立智投1月14日，次新股鷹瞳科技近日股價強勢上漲，實現4連陽，今日午後持續拉昇，高見41.8港元，漲幅15.3%，自低點反彈逾35%。
近日，瑞銀、中信裏昂、招銀國際、安信國際和海通國際等多家投行陸續發佈了對醫療AI企業鷹瞳科技的首次覆蓋研究報告，均首予公司“買入”或“優於大市”評級，目標價分別爲75.2港元、100港元、95.32港元、89.5港元、93.6港元。
瑞銀指，鷹瞳科技成立於2015年，是一家人工智能公司，專注於基於視網膜的早期檢測、診斷和健康風險評估解決方案，認爲公司是AI視網膜影像領域的領導者，雖然該領域仍處於早期階段，但有可能在2025年發展至47億人民幣的市場。瑞銀指，投資者對鷹瞳科技的擔憂是行業的市場規模和競爭力，相信公司可以在未來12個月內逐步達到關鍵裏程碑，證明增長潛力。
中信裏昂研報指，鷹瞳科技是視網膜影像AI領域的領導者，提供基於視網膜影像AI技術的疾病早期檢測、診斷和健康風險評估方案。公司針對糖尿病視網膜病變的Airdoc-AIFUNDUS (1.0) 是首款獲得國家藥監局第三類醫療器械證書的人工智能視網膜影像識別輔助診斷產品。Airdoc-AIFUNDUS (2.0) 和 (3.0) 預計將於2023年和2025年推出，其他幾款獨立的SaMD產品也將於2022年至2025年陸續推出。鷹瞳科技的健康風險評估方案將進一步提升在藥店、保險公司、視光中心和體檢中心等場景中的滲透率。綜合以上因素，考慮到公司診斷產品的無創性和未來龐大的視網膜影像AI市場空間，基於DCF估值模型，該行給公司目標價100港元，首次覆蓋給予“買入”評級。
1月11日，由中國互聯網新聞中心主辦的“2021中國網•科技企業先鋒榜”評選結果正式公佈，鷹瞳科技獲評“2021年度品牌影響力企業”。這意味着作爲“醫療AI第一股”的鷹瞳科技，其商業價值和社會價值實踐再獲權威認可。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
